FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3091751520> ?p ?o ?g. }

• W3091751520 endingPage "e0239191" @default.
• W3091751520 startingPage "e0239191" @default.
• W3091751520 abstract "Background This study aimed to determine the incidence and factors associated with treatment failure among HIV infected adolescent and adult patients on second-line antiretroviral therapy (ART) in public hospitals of Northern Ethiopia. Methods A retrospective study was conducted from September 1, 2007 to July 30, 2017 on 227 patients. The data were extracted using a retrieval checklist from the patient’s charts. The incidence rate of treatment failure was calculated using Kaplan–Meier methods and Cox proportional hazard model was used to assess factors associated with treatment failure. Result The study subjects were followed for a total observation of 788.58 person-years with a median follow-up period of 35 (IQR: 17–60) months after switching to second-line ART. About 57 (25.11%) patients developed treatment failure, out of which, 32 (56.14%) occurred during the first two years. The overall incidence of second-line treatment failure was 72.3 per 1000 person years (95%CI: 55.75–93.71) of observation. The Kaplan–Meier estimates of cumulative treatment failure after 1, 2, and around 10 years of follow-up were 12.31% (95%CI: 8.60–17.45%), 14.99% (95%CI: 10.82%-20.57%), and 48.67% (95%CI: 32.45–67.81%) respectively. Age >45 years AHR = 3.33, 95%CI = 1.33–8.31), WHO stage IV (AHR = 3.63, 95%CI = 1.72–7.67), CD4 count <100 cells/mm3 (AHR = 3.79, 95%CI = 1.61–8.91), TB co-morbidity (AHR = 3.39 95%CI = 1.91–6.01) and poor adherence level (AHR = 3.63, 95% CI = 1.89–6.96) at the start of second line ART were significantly associated with second-line ART failure. Conclusion Incidence of second-line ART treatment failure in the first 2 years of follow-up was high. The rate of second-line ART failure was higher in patients who started second-line ART with poor drug adherence, CD4 count <100 cells/mm3, TB co-morbidity, age >45 years, and being in WHO stage IV. Therefore, intensive counseling and adherence support should be given along with strong TB screening. Moreover, the government of Ethiopia should consider endorsing third-line ART drugs after careful cost–benefit analysis." @default.
• W3091751520 created "2020-10-08" @default.
• W3091751520 creator A5005051627 @default.
• W3091751520 creator A5007487345 @default.
• W3091751520 creator A5020657739 @default.
• W3091751520 creator A5022475950 @default.
• W3091751520 creator A5034787199 @default.
• W3091751520 creator A5048249881 @default.
• W3091751520 creator A5087040858 @default.
• W3091751520 date "2020-09-28" @default.
• W3091751520 modified "2023-10-16" @default.
• W3091751520 title "Incidence and factors associated with treatment failure among HIV infected adolescent and adult patients on second-line antiretroviral therapy in public hospitals of Northern Ethiopia: Multicenter retrospective study" @default.
• W3091751520 cites W1988612814 @default.
• W3091751520 cites W1994475810 @default.
• W3091751520 cites W2011557435 @default.
• W3091751520 cites W2021549847 @default.
• W3091751520 cites W2037720442 @default.
• W3091751520 cites W2042014721 @default.
• W3091751520 cites W2084921375 @default.
• W3091751520 cites W2110784731 @default.
• W3091751520 cites W2133325345 @default.
• W3091751520 cites W2149606648 @default.
• W3091751520 cites W2166121003 @default.
• W3091751520 cites W2335165232 @default.
• W3091751520 cites W2560246813 @default.
• W3091751520 cites W2595821153 @default.
• W3091751520 cites W2614235498 @default.
• W3091751520 cites W2622807149 @default.
• W3091751520 cites W2961430705 @default.
• W3091751520 cites W2964910252 @default.
• W3091751520 cites W2994928278 @default.
• W3091751520 cites W3000628627 @default.
• W3091751520 doi "https://doi.org/10.1371/journal.pone.0239191" @default.
• W3091751520 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7521713" @default.
• W3091751520 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32986756" @default.
• W3091751520 hasPublicationYear "2020" @default.
• W3091751520 type Work @default.
• W3091751520 sameAs 3091751520 @default.
• W3091751520 citedByCount "13" @default.
• W3091751520 countsByYear W30917515202019 @default.
• W3091751520 countsByYear W30917515202021 @default.
• W3091751520 countsByYear W30917515202022 @default.
• W3091751520 countsByYear W30917515202023 @default.
• W3091751520 crossrefType "journal-article" @default.
• W3091751520 hasAuthorship W3091751520A5005051627 @default.
• W3091751520 hasAuthorship W3091751520A5007487345 @default.
• W3091751520 hasAuthorship W3091751520A5020657739 @default.
• W3091751520 hasAuthorship W3091751520A5022475950 @default.
• W3091751520 hasAuthorship W3091751520A5034787199 @default.
• W3091751520 hasAuthorship W3091751520A5048249881 @default.
• W3091751520 hasAuthorship W3091751520A5087040858 @default.
• W3091751520 hasBestOaLocation W30917515201 @default.
• W3091751520 hasConcept C10515644 @default.
• W3091751520 hasConcept C120665830 @default.
• W3091751520 hasConcept C121332964 @default.
• W3091751520 hasConcept C126322002 @default.
• W3091751520 hasConcept C167135981 @default.
• W3091751520 hasConcept C187212893 @default.
• W3091751520 hasConcept C207103383 @default.
• W3091751520 hasConcept C44249647 @default.
• W3091751520 hasConcept C50382708 @default.
• W3091751520 hasConcept C61511704 @default.
• W3091751520 hasConcept C71924100 @default.
• W3091751520 hasConcept C72563966 @default.
• W3091751520 hasConcept C88879693 @default.
• W3091751520 hasConceptScore W3091751520C10515644 @default.
• W3091751520 hasConceptScore W3091751520C120665830 @default.
• W3091751520 hasConceptScore W3091751520C121332964 @default.
• W3091751520 hasConceptScore W3091751520C126322002 @default.
• W3091751520 hasConceptScore W3091751520C167135981 @default.
• W3091751520 hasConceptScore W3091751520C187212893 @default.
• W3091751520 hasConceptScore W3091751520C207103383 @default.
• W3091751520 hasConceptScore W3091751520C44249647 @default.
• W3091751520 hasConceptScore W3091751520C50382708 @default.
• W3091751520 hasConceptScore W3091751520C61511704 @default.
• W3091751520 hasConceptScore W3091751520C71924100 @default.
• W3091751520 hasConceptScore W3091751520C72563966 @default.
• W3091751520 hasConceptScore W3091751520C88879693 @default.
• W3091751520 hasFunder F4320325740 @default.
• W3091751520 hasIssue "9" @default.
• W3091751520 hasLocation W30917515201 @default.
• W3091751520 hasLocation W30917515202 @default.
• W3091751520 hasLocation W30917515203 @default.
• W3091751520 hasOpenAccess W3091751520 @default.
• W3091751520 hasPrimaryLocation W30917515201 @default.
• W3091751520 hasRelatedWork W2010197553 @default.
• W3091751520 hasRelatedWork W2010631330 @default.
• W3091751520 hasRelatedWork W2125345233 @default.
• W3091751520 hasRelatedWork W2581226876 @default.
• W3091751520 hasRelatedWork W2994686985 @default.
• W3091751520 hasRelatedWork W3136232645 @default.
• W3091751520 hasRelatedWork W4225134093 @default.
• W3091751520 hasRelatedWork W4281722959 @default.
• W3091751520 hasRelatedWork W4379796428 @default.
• W3091751520 hasRelatedWork W4380448775 @default.
• W3091751520 hasVolume "15" @default.
• W3091751520 isParatext "false" @default.
• W3091751520 isRetracted "false" @default.

• next